3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
28
Neoplasm Metastasis
9
Neoplasms
8
Brain Neoplasms
5
Ovarian Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms by Site
3
Glioma
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Liposarcoma
2
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
29
Rituximab
23
fludarabine
15
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Whole-Body Irradiation
8
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Peripheral Blood Stem Cell Transplantation
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
abemaciclib
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled